COMPANY:

Vyant Bio

"Vyant Bio, Inc...announces a collaboration that will seek to de-risk the development of small protein therapeutics. In partnership with Ordaōs Bio (“Ordaōs”) and Cellaria, Inc. (“Cellaria”), the Company is unveiling a model for rapid iteration of therapeutic design using artificial intelligence and in vitro ‘avatar clinical trials’ that will enable the design, development, and testing of potential therapeutics on specific patient populations, during preclinical development. The goal is to provide an early detection system of a drug’s efficacy in different patient cohorts, prior to clinical trials."

"Cancer Genetics, Inc...and StemoniX, Inc...today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. ('Vyant Bio') effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of the Company."

"Cancer Genetics, Inc...announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ('StemoniX'). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Common Stock, warrants and options pursuant to the Agreement and Plan of Merger and Reorganization, dated as of August 21, 2020, as amended, with StemoniX."